文献速递认知障碍与痴呆

低剂量阿司匹林对痴呆与认知下降影响的随机安慰剂对照试验

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
PubMed 文献 · Neurology · 2020-03-25

ASPREE试验纳入19114名无心血管疾病和痴呆的社区老年人,随机接受每日100mg阿司匹林或安慰剂,中位随访4.7年。结果显示阿司匹林未显著降低全因痴呆、很可能阿尔茨海默病、轻度认知障碍或认知下降的风险。

要点

  • 低剂量阿司匹林未显著降低全因痴呆风险(HR 1.03,95%CI 0.91-1.17)。
  • 很可能阿尔茨海默病风险无显著差异(HR 0.96,95%CI 0.74-1.24)。
  • 轻度认知障碍风险无显著差异(HR 1.12,95%CI 0.92-1.37)。

核心结论

  • 无证据表明阿司匹林可有效降低痴呆、轻度认知障碍或认知下降的风险。

研究设计与样本

  • ASPREE为双盲、安慰剂对照试验,纳入美国与澳大利亚社区居住的≥70岁(美国少数族裔≥65岁)无心血管疾病、躯体残疾和痴呆的个体19114名,随机1:1接受每日100mg阿司匹林或安慰剂。

主要发现

  • 中位随访4.7年,964人触发进一步痴呆评估,575例裁定为痴呆,其中41%分类为临床很可能阿尔茨海默病。
  • 阿司匹林与安慰剂组全因痴呆触发风险无实质差异(HR 1.03,95%CI 0.91-1.17)。
  • 很可能阿尔茨海默病风险无显著差异(HR 0.96,95%CI 0.74-1.24)。
  • 轻度认知障碍风险无显著差异(HR 1.12,95%CI 0.92-1.37)。
  • 两组认知随时间变化相似。

关键数值与推荐

  • 痴呆裁定依据DSM-IV标准,阿尔茨海默病和轻度认知障碍亚分类采用美国国家老龄研究所-阿尔茨海默病协会标准。

临床怎么用

  • 对于健康老年人,低剂量阿司匹林不应作为降低痴呆或认知下降风险的干预措施。

局限性

  • 初始暴露后这些结局的随访仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. METHODS: Aspirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled trial of low-dose aspirin. In the United States and Australia, community-dwelling individuals aged ≥70 years (US minorities ≥65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled. Participants were randomized 1:1-100 mg daily aspirin or placebo. The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition at baseline and over follow-up. Additional cognitive testing was performed in participants with suspected dementia ("trigger") based on within-study assessments or clinical history. Dementia was adjudicated according to DSM-IV criteria. National Institute on Aging-Alzheimer's Association criteria were used for AD and MCI subclassification. RESULTS: A total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments. There were 575 adjudicated dementia cases, and 41% were classified as clinically probable AD. There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo. Cognitive change over time was similar in the aspirin and placebo groups. CONCLUSIONS: There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. Follow-up of these outcomes after initial exposure is ongoing. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline. CLINICALTRIALSGOV IDENTIFIER: NCT01038583.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ryan J, Storey E, Murray AM, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 2020. PMID: 32213642. doi:10.1212/WNL.0000000000009277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。